<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="307999">
  <stage>Registered</stage>
  <submitdate>1/06/2009</submitdate>
  <approvaldate>15/03/2010</approvaldate>
  <actrnumber>ACTRN12610000210077</actrnumber>
  <trial_identification>
    <studytitle>Preventing pneumococcal disease in people without spleens (asplenia) and with poorly functioning spleens (hyposplenia)</studytitle>
    <scientifictitle>In patient without spleens or with poorly functioning ones does a newly licensed paediatric pneumococcal conjugate vaccine assist with preventing pneumococcal sepsis in preventing deaths or severe impairments (which are very costly) from overwhelming post splenectomy sepsis</scientifictitle>
    <utrn />
    <trialacronym>PAPI Prevention of Asplenic Pneumococcal infection</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Improving and sustaining pneumococcal antibodies in asplenic patients</healthcondition>
    <healthcondition>Better understanding of pneumococcal vaccine regimes in asplenic/hyposplenic patients</healthcondition>
    <healthcondition>Asplenia and Hyposplenia</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Health service research</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Asplenic adults and children aged over 10 years will be administered a licensed pneumococcal 10 valent conjugate vaccine (Synflorix). This is a 10 valent polysaccharide-protein conjugate vaccine containing saccharides of the capsular antigen of Streptococcus pneumoniae (pneumococcus) serotypes 1,4, 5 6B, 7F,  9V, 14, 18C, 19F and 23F individually conjugated to protein D (PD) carrier protein derived from Non-typable Haemophilus inlfuenzae, serotype 18C conjugated to tetanus toxoid (TT) carrier protein, and 19F conjugated to diphtheria toxoid (DT) carrier protein. It will be given once to patients in 3 arms of the study and omitted from the 4th arm (they will have pneumococcal polysaccharide vaccine only).</interventions>
    <comparator>We will be inviting people over 10 years of age and adults, without spleens, to be randomised to have either the pneumococcal conjugate vaccine (Synflorix) or the polysaccharide vaccine (Pneumovax 23). There are 4 arms to the study and they vary according to the times thay are adminstered. Synflorix vaccine is a 10 valent polysaccharide-protein conjugate vaccine containing saccharides of the capsular antigen of Streptococcus pneumoniae (pneumococcus) serotypes 1,4, 5 6B, 7F,  9V, 14, 18C, 19F and 23F individually conjugated to protein D (PD) carrier protein derived from Non-typable Haemophilus inlfuenzae, serotype 18C conjugated to tetanus toxoid (TT) carrier protein, and 19F conjugated to diphtheria toxoid (DT) carrier protein. Both vaccines are given intramuscular injection (IMI). Patients will have a 1:4 chance of receiving Pneumovax 23 and a 3:4 chance of receiving the pneumococcal conjugate vaccine. Both are licensened vaccines - the Synflorix is only licensed for children.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objectives
Primary
1(a)  To describe the serotype specific immune response in Streptococcus pneumoniae (SP) polysaccharide vaccine  (PPV23) naive and experienced hyposplenic adults and children &gt;10 years of age 6 weeks following Streptococcus pneumoniae SP conjugate vaccine (PCV10) as measured by quantitative enzyme-linked immunosorbent assay  (ELISA) geometric mean titre (GMT)
1(b)  To describe the functional serotype specific immune response in SP polysaccharide (PPV23) vaccine naive and experienced hyposplenic adults and children &gt;10 years of age 6 weeks following Streptococcus pneumoniae SP conjugate vaccine (PCV10) as measured by the opsonophagocytic assay (OPA) geometric mean titre (GMT) 

2(a)  To compare the quantitative serotype specific immune response as measured by the ELISA geometric mean concentration (GMC) 6 weeks after receiving a first dose of PPV23 performed 6 weeks (early) or 6 months (late) after PCV10 vaccination in adults and children who have not previously been exposed to PPV23 vaccine 
2(b)  To compare the functional serotype specific immune response 6 weeks as measured by the OPA GMT after receiving a first dose of PPV23 performed 6 weeks (early) or 6 months (late) after PCV10 vaccination in adults and children who have not previously been exposed to PPV23 vaccine 

3 In PPV23 experienced hyposplenic adults and children, describe the immune persistence prior to revaccination with PCV10 or PPV23 of serotype specific antibodies against 10 serotypes contained in PPV23 prior to revaccination, measured by ELISA.

4(a)  In PPV23 experienced hyposplenic adults and children compare quantitative serotype specific ELISA immune responses to (a) PCV10 followed by PPV23, with (b) PPV23, measured 6 weeks following PPV23
4(b)  In PPV23 experienced hyposplenic adults and children compare functional serotype specific OPA immune responses to (a) PCV10 followed by PPV23, with (b) PPV23, measured 6 weeks following PPV23</outcome>
      <timepoint>Visit 1 (day 0) The Investigator (or delegate) must obtain the written informed consent of the participant or parent(s)/guardian(s) according to local laws and requirements before any study-related procedures are performed. Once consent has been obtained the full eligibility check list will be assessed.

Participants who meet all of the inclusion and none of the exclusion criteria and have provided written consent will be allocated to one of 4 treatment groups according to their previous exposure to PCV23 (those with previous exposure randomised between Groups 1 and 2 and those with no exposure between Groups 3 and 4).

The following procedures will be conducted prior to randomisation and the results recorded in the participant's case report forms (CRFs): Medical history (including immunisation history),	Demographic data (date of birth, gender, weight, height).Vital signs including temperature (using a digital thermometer), (supine, if possible) blood pressure, pulse and respiratory rate.
Blood samples: full blood examination, pneumococcal ELISA, opsonophagocytic assay). Review of prior and concomitant medication.  Once randomised, study vaccines will be administered according to group allocation:
Groups 1-3: PCV10
Groups 4: PPV23
 At this time concomitant licensed vaccines will also be administered if indicated and requested by treating physician, including any of:Meningococcal vaccine, Haemphilus influenzae type b vaccine, Influenza vaccine
Participants will be required to complete a 7-Day Diary Card (to record and grade the severity of solicited adverse events (AEs)) for the next 6 days following administration of the vaccine (commencing on the evening of the day of administration). The participant will be given a study thermometer  along with instructions on its use.
Visit 2 (6 week visit) The following procedures will be conducted and the results recorded in the participant's medical records and CRF: Brief targeted examination by the research nurse noting any changes since previous visit will be conducted. Measurement of vital signs (oral/axillary temperature, blood pressure, pulse and respiratory rate). Record any AEs that have occurred since the last visit 
Review of concomitant medication.
Blood samples for: Immunogenicity (pneumococcal ELISA, opsonophagocytic assay).
Groups 1 and 3 only: give pneumococcal polysaccharide vaccine (PPV). Ask participant to complete the 7-Day Diary Cards and provide instruction for their completion. Diary Card completion should commence on the evening of Visit 2. Instruct the participant or parent(s)/guardian(s) to contact the Investigator immediately if any significant illness or any hospitalisation occurs during the study period, or if temperature &gt;37.5 degrees celsius.
Visit 3 (3 months: Groups 1 and 3 only)
A brief targeted examination by the research nurse noting any changes since previous visit will be conducted 
Blood samples for Immunogenicity (pneumococcal ELISA, opsonophagocytic assay), Record and review AEs, Collection and review of concomitant medication.
Visit 4 (6 months: Group 2 only)
A brief targeted examination by the research nurse noting any changes since previous visit will be conducted 
Blood samples for:Immunogenicity (pneumococcal ELISA, opsonophagocytic assay), Record and review AEs. Collection and review of concomitant medication.
Administer study vaccine: PPV. 
Visit 5 (7.5 months: Group 2 only)
A brief targeted examination by the research nurse noting any changes since previous visit will be conducted, Record and review AEs, Collection of 7-Day Diary Card and review of concomitant medication, Blood samples for Immunogenicity (pneumococcal ELISA, opsonophagocytic assay)
Completion visit 6 (18 months): Visit 4 (Group 1 &amp; 3), Visit 6 (Group 2), Visit 3 (Groups 4) A brief targeted examination by the research nurse noting any changes since previous visit will be conducted, Record and review AEs and serious adverse events (SAEs), Review of concomitant medications and vaccines during study period.Blood samples for:
Immunogenicity (pneumococcal ELISA, opsonophagocytic assay)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Persistence of serotype specific anti-pneumococcal antibodies as measured by ELISA antibodies</outcome>
      <timepoint>see above in timepoint 1</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>People with a histroy of splenectomy (asplenia) and those with a diagnosis of hyposplenism that is confirmed by presence of Howell Jolly bodies (HJBs) on blood film. To participate in trial patients must be over 10 years of age.</inclusivecriteria>
    <inclusiveminage>10</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>STUDY PARTICIPANTS: Patients who (i) could not comply with study commitments (ii) receiving cancer therapy, (iii) received pneumococal polysaccharide vaccine in previous three years</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Asplenic subjects, according to their prior PPV23 experience categories (naive 2 or experienced) in each category will be prospectively randomised to one of two treatment groups (Naive 2 to Groups 1 or 2; Experienced to Groups 3 or 4) in a 1:1 ratio, according to a randomisation schedule generated by the Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research Iinstitue/Royal Children's Hospital.</concealment>
    <sequence>Randomisation will be stratified by previous exposure to PPV23, site and participantâ€™s age, giving a total of 12 strata.  The randomisation schedule will be computer generated using block randomisation with random block sizes by Clinical Epidemiology and Biostats Unit (CEBU) at RCH who will keep a confidential copy.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Multicentre</designfeatures>
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>20/03/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3004</postcode>
    <postcode>3025</postcode>
    <postcode>2034</postcode>
    <postcode>3168</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Health and Medical Research</primarysponsorname>
    <primarysponsoraddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Murdoch Childrens Research Institute, Royal Children's Hospital</sponsorname>
      <sponsoraddress>Flemington Rd, Parkville Victoria 3052,</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Alfred hospital</othercollaboratorname>
      <othercollaboratoraddress>Commercial Road
Melbourne Victoria 3004</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Background

There are thousands of Australians who live without a spleen (asplenia) or have a poorly functioning one (hyposplenia). These people are at a significantly increased risk of life-threatening infections (sepsis).The spleens main function is to remove bacteria (bugs) from the blood and therefore plays a very important role in the bodys immune system. The most common bacteria that causes problems for people without or with poorly functioning spleens is the pneumococcus bacteria. Asplenic/hyposplenic patients are more than 200 times more likely to develop pneumococcal sepsis than those with normal spleen function. The mortality rate from pneumococcal sepsis for patients without functioning spleens is extremely high at 40-70%. Even if patients do survive they can be left with severe impairment (morbidity). It is well known that this increased risk of acquiring severe sepsis is a lifelong risk with the majority of life-threatening episodes of infection occurring more than 10 years after spleen removal.


Patients that take antibiotics every day have been shown to have some protection against pneumococcal sepsis. Asplenic/hyposplenic patients are also routinely vaccinated against pneumococcus in an attempt to reduce morbidity and mortality. It is currently not very clear to medical practitioners what the optimal vaccine regimes are to protect this group of patients against pneumococcus, either initially, or for repeat immunisations later in life. Newer pneumococcal vaccines have proven safe and effective in reducing pneumococcal sepsis in young children and may also offer promise for asplenic/hyposplenic older children and adults in addition to the existing pneumococcal vaccine. 

2.	What is the purpose of this study?

This study aims to identify the best way to immunise children and adults, who either do not have a spleen or have a poorly functioning one, against pneumococcal disease. There are three main ways to prevent getting bacterial infections in people like you. These are (i) taking antibiotics every day and/or having an emergency supply of antibiotics, (ii) immunisations and (iii) education. However sometimes patients, despite following the recommendations, get pneumococcal infections. Many pneumococcal vaccine research studies in the past have not included people without spleens or poorly functioning ones, so little is known about how these patients respond to the well known vaccinations. 

There are some new pneumococcal vaccines that have been shown to work better in young children than the older type vaccines. The study team is particularly interested in finding out if these newer vaccines might, in addition to using the routine vaccines, provide better antibody levels to protect against pneumococcal disease and will give the researchers information on when is the best time to administer the new vaccine, This vaccine study will not only target older children and adults who have not had any previous doses of pneumococcal vaccines but it will also include those who may have had at least one pneumococcal vaccine and or those who will require further booster doses of vaccine. 

3.	How many people are involved in this study?

This study will be conducted in three sites in Melbourne (the Royal Childrens Hospital, Monash Medical Centre and The Alfred hospital) and a further site in Sydney (Prince of Wales Hospital). A total of 220 people will be invited to participate, 110 participants who have previously received the routinely used pneumococcal polysaccharide vaccine (PPV23) and 110 people who have not. Participants will be adults and children aged over 10 years who are asplenic/hyposplenic. 

4.	What type of research is this study?

This is a study comparing different ways of immunising asplenic/hyposplenic children and adults to see which gives the highest and longer lasting levels of protective antibodies against pneumococcus.

Children and adults with asplenia/hyposplenia will be randomly assigned (like flipping a coin) to one of two treatment groups based on whether or not they have previously received the PPV23 vaccine. 

This research study has been reviewed and approved by the Human Research Ethics Committee at each of the four hospital sites. It is the role of this committee to make sure that research participants are protected from harm.</summary>
    <trialwebsite>No specific website however there will be information about this trial on the Victiorian Spleen Registry (VSR) website - www.spleen.org.au</trialwebsite>
    <publication>nil yet</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Health</ethicname>
      <ethicaddress>Alfred Hospital, Hospital Research Ethics Committee, Commercial Road, Prahran Victoria 3181</ethicaddress>
      <ethicapprovaldate>11/06/2009</ethicapprovaldate>
      <hrec>HREC 161/09</hrec>
      <ethicsubmitdate>20/05/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Jim Buttery</name>
      <address>Murdoch Childrens Research Institute, Royal Childrens Hospital, Flemington Road, Parkville Victoria 3052</address>
      <phone>61 3 9345 4772</phone>
      <fax>61 3 9345 4163</fax>
      <email>jim.buttery@mcri.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Penelope Jones</name>
      <address>Victorian Spleen Registry
85 Commercial Road
Melbourne Victoria 3004</address>
      <phone>61 3 9076 3828</phone>
      <fax>61 3 9076 2431</fax>
      <email>p.jones@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Penelope Jones</name>
      <address>Victorian Spleen Registry
85 Commercial Road
Melbourne Vic 3004</address>
      <phone>61 3 9076 3828</phone>
      <fax>61 3 9076 2431</fax>
      <email>p.jones@alfred.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>